Evidence map›Paper›PMID 38258074›Full record

ArticlePharmaceutics2023

Assessing

John T Powell, Ruhul Kayesh, Alexandra Ballesteros-Perez, Khondoker Alam, Pascaline Niyonshuti, Erik J Soderblom, Kai Ding, Chao Xu, Wei Yue

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

John T PowellDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.ORCID 0009-0003-0378-8753
Ruhul KayeshDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Alexandra Ballesteros-PerezDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Khondoker AlamDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Pascaline NiyonshutiDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
Erik J SoderblomProteomics and Metabolomics Core Facility, Duke University School of Medicine, Durham, NC 27708, USA.
Kai DingDepartment of Biostatistics & Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Chao XuDepartment of Biostatistics & Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.ORCID 0000-0002-3821-6187
Wei YueDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
University of Oklahoma Health Sciences Center · USDuke University · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ROBERT S. MANNEL · 2018 to 2026
$27.1M
FV 10i-LIV Conofocal Imaging System (GM094268)R01GM094268 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI YUE, WEI · 2011 to 2015
$1.5M
Regulation of OATP1B1 and OATP1B3 by lysine acetylation and lysine deacetylase inhibitorsR01GM146956 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI YUE, WEI · 2022 to 2025
$1.3M
Thermo Lumos Tribrid High-Resolution Accurate-Mass Tandem Mass SpectrometerS10OD024999 · OD · DUKE UNIVERSITY · PI MOSELEY, MARTIN ARTHUR · 2018 to 2018
$600k
NCI NIH HHS P30 CA225520NIGMS NIH HHS GM146956-01NIGMS NIH HHS R01 GM094268NIGMS NIH HHS R01 GM146956NIH HHS S10 OD024999
6 · The paper itself

Abstract

Organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 are key determinants of drug-drug interactions (DDIs). Various drugs including the calcineurin inhibitor (CNI) cyclosporine A (CsA) exert preincubation-induced

Indexed as

calcineurincyclosporine Adrug–drug interactionsdrug transportOATP1B1OATP1B3organic anion transporting polypeptideSCY-635tacrolimustrans-inhibition

Identifiers

PMID38258074
PMCPMC10818623
OpenAlexW4390467310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.